Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa

Affiliations

¹ Africa Centers for Disease Control and Prevention, Addis Ababa, Ethiopia; National Public Health Laboratory, Yaoundé, Cameroon. Electronic address: TemfackE@africa-union.org.
² Molecular Mycology Unit, Institut Pasteur of Paris, Paris, France; Department of Infectious and Tropical Diseases, University of Paris Cité, Paris, France; Department of Infectious and Tropical Diseases, Necker Hospital, Paris, France.

Comment

Elvis Temfack et al. Lancet Infect Dis. 2022 Sep.

. 2022 Sep;22(9):1262-1264.

doi: 10.1016/S1473-3099(22)00315-2. Epub 2022 Jun 21.

¹ Africa Centers for Disease Control and Prevention, Addis Ababa, Ethiopia; National Public Health Laboratory, Yaoundé, Cameroon. Electronic address: TemfackE@africa-union.org.
² Molecular Mycology Unit, Institut Pasteur of Paris, Paris, France; Department of Infectious and Tropical Diseases, University of Paris Cité, Paris, France; Department of Infectious and Tropical Diseases, Necker Hospital, Paris, France.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
Mashau RC, Meiring ST, Quan VC, Nel J, Greene GS, Garcia A, Menezes C, Reddy DL, Venter M, Stacey S, Madua M, Boretti L, Harrison TS, Meintjes G, Shroufi A, Trivino-Duran L, Black J, Govender NP; GERMS-SA. Mashau RC, et al. Lancet Infect Dis. 2022 Sep;22(9):1365-1373. doi: 10.1016/S1473-3099(22)00234-1. Epub 2022 Jun 21. Lancet Infect Dis. 2022. PMID: 35750065 Free PMC article.